The SU2C Gynecologic Cancers Convergence Research Team studies immune defects in gynecologic cancer patients with highly mutated tumors to gain insights into immune responsiveness. The scientists are working to predict therapeutic outcomes and tailor treatment regimens for this subset of gynecologic cancers.